Agbalalah, T., Robert, F
Lurking underneath the whole conversation of GLP-1s and eating disorders is the difficult truth that cultural fatphobia contributes to the prevalence of eating disorders, says Maria Rago, a psychologist in Illinois and the president of the board of directors for the National Association of Anorexia Nervosa and Associated Disorders

Eli Lilly and Company reports P-III (TRIUMPH-1) trial results for triple agonist retatrutide, demonstrating up to 28.3% mean weight loss at 80 weeks and 30.3% at 104 weeks in adults with obesity or overweight without diabetes Subscribe to our weekly newsletter and never miss a beat: #elililly #retatrutide #triumph1 #obesity #overweight #piii #diabetes #weightloss #clinicaltrial PharmaShots Post Eli Lilly and Company reports P-III (TRIUMPH-1) trial results for triple agonist retatrutide, demonstrating up to 28.3% mean weight loss at 80 weeks and 30.3% at 104 weeks in adults with obesity or overweight without diabetes Subscribe to our weekly newsletter and never miss a beat: #elililly #retatrutide #triumph1 #obesity #overweight #piii #diabetes #weightloss #clinicaltrial More from this author PharmaShots Weekly | Jul 27, 2026 Edition CXO Talks Podcast | Building Smarter Biotech: Venkat Nelabhotla, CEO of Vyome Holdings, on Driving Innovation Across the USIndia Corridor Gona Aziz at HLTH Europe 2026 on the Convergence of AI & 5T MRI: United Imagings Strategy for Advancing Precision Healthcare

The Science Behind AOD-9604 and Weight Loss AOD-9604 was designed by isolating the lipolytic (fat-burning) region of the HGH moleculespecifically, amino acids 176-191
These novel therapies have often exceeded expectations by demonstrating beneficial effects that extend to complications that were not the primary focus of their development
Its a much better deal than paying $1,000 per month or more out-of-pocket for name-brand prescriptions that are only sometimes covered by insurance, but, like most good things, those deals come with a pretty big asterisk